Abstract
The purpose of these guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion SPECT studies using Tc-99m radiopharmaceuticals and brain metabolism PET studies using F-18 fluorodeoxyglucose (FDG). These guidelines have been adapted and extended from those produced by the Society of Nuclear Medicine (Juni et al., 1998) and the European Association of Nuclear Medicine by a Belgian group of experts in the field trained in neurology and/or nuclear medicine. Some indications are not universally approved (e.g. brain death), but largely supported by the literature. They have been included in these guidelines in order to provide recommendations and a standardised protocol.
Publication types
-
Guideline
-
Practice Guideline
MeSH terms
-
Acetazolamide / administration & dosage
-
Adult
-
Brain / diagnostic imaging*
-
Brain / metabolism
-
Brain Death / diagnostic imaging
-
Cerebrovascular Disorders / classification
-
Cerebrovascular Disorders / diagnostic imaging
-
Child
-
Craniocerebral Trauma / diagnostic imaging
-
Dementia / diagnostic imaging
-
Diagnosis, Differential
-
Epilepsy / diagnostic imaging
-
Fasting
-
Fluorodeoxyglucose F18 / administration & dosage
-
Humans
-
Image Processing, Computer-Assisted
-
Parkinson Disease / diagnosis
-
Parkinson Disease / diagnostic imaging
-
Radiopharmaceuticals / administration & dosage
-
Subarachnoid Hemorrhage / diagnostic imaging
-
Technetium / administration & dosage
-
Tomography, Emission-Computed / standards*
-
Tomography, Emission-Computed, Single-Photon / standards*
Substances
-
Radiopharmaceuticals
-
Fluorodeoxyglucose F18
-
Technetium
-
Acetazolamide